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AbstrACt
Purpose Depression is the most common psychiatric 
disorder and the largest contributor to global disability. The 
Australian Genetics of Depression study was established 
to recruit a large cohort of individuals who have been 
diagnosed with depression at some point in their lifetime. 
The purpose of establishing this cohort is to investigate 
genetic and environmental risk factors for depression and 
response to commonly prescribed antidepressants.
Participants A total of 20 689 participants were recruited 
through the Australian Department of Human Services 
and a media campaign, 75% of whom were female. The 
average age of participants was 43 years±15 years. 
Participants completed an online questionnaire that 
consisted of a compulsory module that assessed self- 
reported psychiatric history, clinical depression using 
the Composite Interview Diagnostic Interview Short 
Form and experiences of using commonly prescribed 
antidepressants. Further voluntary modules assessed 
a wide range of traits of relevance to psychopathology. 
Participants who reported they were willing to provide a 
DNA sample (75%) were sent a saliva kit in the mail.
Findings to date 95% of participants reported being 
given a diagnosis of depression by a medical practitioner 
and 88% met the criteria for a lifetime depressive episode. 
68% of the sample report having been diagnosed with 
another psychiatric disorder in addition to depression. 
In line with findings from clinical trials, only 33% of the 
sample report responding well to the first antidepressant 
they were prescribed.
Future plans A number of analyses to investigate 
the genetic architecture of depression and common 
comorbidities will be conducted. The cohort will contribute 
to the global effort to identify genetic variants that increase 
risk to depression. Furthermore, a thorough investigation 
of genetic and psychosocial predictors of antidepressant 
response and side effects is planned.
IntroduCtIon
Approximately 20% of Australians will be 
diagnosed with a depressive disorder in 
their lifetime. As a consequence of this 
high prevalence, impact on function and 
risk to later ill- health and premature death, 
depressive disorders contribute the largest 
burden of disease due to common mental 
disorders1 2 and place a substantial burden on 
the economy in terms of days lost to disability.
Among psychiatric disorders, depression 
is moderately heritable, with approximately 
40% of the variance in liability to depression 
attributable to genetic factors.3 Initial efforts 
to identify depression risk variants using 
genome- wide association studies (GWASs) 
did not bear fruit due to insufficient power.4 
Common genetic variants for psychiatric 
disorders have small effect sizes and hence 
sample sizes in the tens of thousands of indi-
viduals are needed in order to robustly detect 
them.5 Substantial progress has been made in 
the last few years in identifying genetic vari-
ants that increase risk to depressive symptoms 
and major depression.6–8 These discoveries 
have been facilitated by the collaboration 
of researchers worldwide in the Psychiatric 
Genomics Consortium (PGC). The most 
recent GWAS for depression which included 
data from the PGC, the personal genetics 
company 23andMe, the UK Biobank and 
DeCODE, identified 102 independent genetic 
variants that increase risk of depression.9 The 
strengths and limitations of this study
 ► This study is one of the largest cohorts in the world 
for studying genetic and psychosocial risk factors 
for depression and response to antidepressants.
 ► Wide range of measures collected using the online 
instrument including diagnostic screening question-
naires for depression and anxiety disorders.
 ► Access to government medical and pharmaceutical 
records.
 ► Low rates of response to the letters sent through 
the pharmaceutical benefits scheme and high ed-
ucational attainment of the cohort may indicate a 
self- selection bias.
 ► Online assessment allowed for recruitment of a 
large sample but there may be biases attributable 
to self- report measures and it was not possible to 
clarify with participants if there were inconsistencies 
in their responses.
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Figure 1 Schematic of the AD, Antidepressant; AGDS. 
AGDS, Australian Genetics of Depression Study; DHS, 
Department of Human Services; GWAS, genome- wide 
association study; MDD, Major Depressive Disorder; 
PBS, Pharmaceutical Benefits Scheme; PGC, Psychiatric 
Genomics Consortium.
identified variants explain only a fraction of the overall 
liability and larger studies are needed to identify more 
individual variants and to improve the predictive power 
of polygenic risk scores, a measure of the genetic vulner-
ability that an individual possesses. Thus, the psychiatric 
genomics community aims to collect data on 1 million 
cases with depression in order to elucidate the genetics 
of this disorder5
Antidepressants are a frontline treatment for moderate- 
to- severe depression, but do not provide benefit for all 
patients and have side effects, leading to poor adherence 
and reduced quality of life. Variability in response to anti-
depressants and experiencing side effects have a poorly 
understood genetic component.10 11 As they are one of 
the most commonly prescribed medications and many 
individuals are exposed to several different drugs, or 
drug classes, before symptoms improve, there is an urgent 
need to understand the reasons for such wide individual 
variability in therapeutic response and the experience 
of side effects. Results from pharmacogenetic studies of 
response and side effects have been mixed, likely because 
of insufficient sample sizes.12–16
Large studies of deeply phenotyped patients are needed 
to reveal the biological underpinnings of this clinically 
heterogeneous disorder and to better match patients to 
therapies so as to reduce the time to remission. For these 
reasons, we established the Australian Genetics of Depres-
sion Study (AGDS).
objectives
This study had three primary objectives. The first was 
to recruit 10 000 cases with depression in Australia to 
contribute to the global effort to identify genetic variants 
conferring risk to depression. The second was to further 
elucidate genetic and non- genetic risk factors for antide-
pressant response and side effects. The third was to dissect 
genetic heterogeneity in depression by leveraging existing 
GWAS results for depression to investigate whether there 
are differences among subtypes of depression. Our aim 
was to contribute to the wider PGC effort by increasing 
the sample size of cases of depression in order to identify 
genetic variants that increase risk to the disorder, as well 
as antidepressant response. Here we describe the aims 
of the study, the genetic and phenotype data collection 
procedures and the characteristics of the sample.
Cohort desCrIPtIon
design
The AGDS is an analytical study designed to assess the 
contribution of genetic variation to risk of depression and 
therapeutic response to antidepressants. In order to maxi-
mise the sample size for genetic analysis, the focus was 
on recruiting participants who had been diagnosed with 
depression at some point in their life. An online survey 
was used to assess history of depression and use and expe-
riences of antidepressants. Controls for genetic analysis 
come from a separate study conducted in Queensland in 




Participants were recruited to the AGDS ( www. genetic-
sofdepression. org. au) using two separate approaches: 
(1) recruitment based on nationwide, pharmaceutical 
prescription history in the last 4.5 years and (2) a media 
publicity campaign throughout Australia. A schematic of 
the design and aims of the study is shown in figure 1.
Recruitment via pharmaceutical prescription history
The Australian Government subsidises certain healthcare 
services through the Medicare Benefits Scheme (MBS) 
and prescription medications through the Pharmaceu-
tical Benefits Scheme (PBS). Records for the most recent 
4.5 years’ services provided are retained by the Australian 
Government Department of Human Services (DHS). 
While these records are not accessible to researchers 
for the purposes of identifying potential research study 
participants, DHS is able to send invitations on behalf 
of researchers to individuals meeting specific selection 
criteria to invite them to participate in relevant research 
studies.
After receiving approval from the DHS research ethics 
committee, two waves of recruitment were undertaken 
using this method. A pilot study in which DHS sent 10 000 
invitation letters to Australian residents aged 18–30 who 
had received four or more prescriptions in the previous 
4.5 years for any of the 10 most commonly prescribed 
antidepressant medications (single medication or a 
combination) was initiated in September 2016. Only 
community patients were selected; individuals with resi-
dential locations in the PBS database corresponding to 
hospitals, aged- care facilities and correctional facilities 
were excluded as obtaining a saliva sample would not be 
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Figure 2 Overview of the structure and content of the AGDS 
questionnaire with median amount of time taken to complete 
each module during piloting of the questionnaire. AGDS, 
Australian Genetics of Depression Study.
possible. This group of invitees was 65% female, reflecting 
the higher prevalence of depression in women. Potential 
participants were sent a letter by the DHS explaining that 
they were being contacted on behalf of researchers at 
QIMR Berghofer to invite them to participate in a study 
of the genetics of depression. The letter provided details 
of the study website and also a phone number that they 
could contact for more information. A total of 294 indi-
viduals responded to this invitation over a 6- month period 
and enrolled in the study.
The second DHS- based recruitment wave started 
in April 2017 and involved sending 100 000 invitation 
letters using similar selection criteria to the pilot study, 
except that the upper age restriction for participants was 
removed.
Recruitment through media publicity campaign
A Sydney- based public relations company specialising in 
health sector campaigns (VIVA! Communications) was 
contracted to manage the media campaign, which was 
launched on 4 April 2017 and utilised a combination of 
national broadcast, print and social media to promote 
knowledge of and interest in the study among the general 
community. This coincided with the second wave of 
recruitment through DHS. The campaign encouraged 
participation among ‘Australian adults who have been, or 
are continuing to be treated for clinical depression by a 
doctor, psychologist or psychiatrist’. A second wave of the 
media campaign was initiated 6 months after the initial 
one in September 2017 using similar procedures.
Enrolment procedure
In both the DHS recruitment letter and the media public 
appeal, potential participants were asked to go to the study 
website which was hosted on the secure QIMR Berghofer 
server. On going to the website, the information sheet 
which provided details of the aims of the study as well as 
a consent form was available for viewing. The informa-
tion sheet provided telephone and email contact details 
for the study coordinator and institute ethics committee 
in case participants had any questions. Those not inter-
ested in participating were provided with simple instruc-
tions on how to exit the website. The identity of potential 
participants was not known to the researchers prior to 
their decision to enrol in the study. The DHS did not 
provide identifying information to the research team on 
who was mailed. Before being asked to provide any identi-
fying information, prospective participants were asked to 
confirm that they had read and understood the informa-
tion sheet, would be willing to provide a saliva sample for 
genotyping and sign the study informed consent.
On confirming that they would like to enrol in the study, 
participants were asked to provide their name, age and 
contact details which were stored securely on the QIMR 
server. After providing these details, each participant was 
assigned a unique link to the questionnaire which was 
hosted on the Qualtrics website. This transition between 
websites was seamless to the participant. Participation in 
this study was not remunerated.
Record linkage—access to Medicare and PBS records
Participants were also asked to consent to provide access 
to their list of Medicare and PBS records for the previous 
4.5 years, and approximately 75% of participants did so. 
This consent process was separate to the overall consent to 
participate in the study, and participants could still enrol 
in the study without allowing access to these records. 
The consent form had to conform to the requirements 
of the DHS. Participants were shown an example of what 
MBS and PBS records look like prior to consenting so 
they would know what information would be available to 
researchers. Within the MBS and PBS data, the identifiers 
for the providing doctor, medical service or pharmacy are 
randomised so the provider and location are protected. 
It is possible to identify repeated claims from the same 
provider but not who the provider is.
Measures
Development and structure of the questionnaire
The content of the Australian Genetics of Depression 
Study online questionnaire was developed over a period 
of 19 months between January 2015 and September 2016. 
The object was to maximise the amount of clinically rele-
vant information collected with the shortest time commit-
ment required of participants. To this end, we utilised a 
modular structure (figure 2), with a core module eliciting 
essential information on self- report mental health diag-
noses, medication response and side effects, depression 
diagnosis using the relevant section from the Composite 
International Diagnostic Interview (CIDI), screens for 
suicidality, mania and psychosis and a question about 
family history of psychiatric disorders. Several psychi-
atrists in Australia and internationally with expertise in 
gene mapping studies and in studies of antidepressant 
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response were consulted about the content of the 
questionnaire.
Ten additional ‘satellite’ modules assessed a range 
of complex traits of relevance to mental health using 
a variety of scales and questionnaires (figure 2). One 
module screened for clinical anxiety using the CIDI. 
The questionnaire was administered online using the 
Qualtrics software. Responses to individual questionnaire 
items were only required for items critical to phrasing of 
future questionnaire items and skip functionality (eg, age, 
sex, number of children). The satellite modules could 
be completed in any order the participant chose once 
they had completed the core module. Participants were 
able to leave the survey and return at their convenience. 
Rates of completion of the satellite modules are shown in 
online supplementary table 1. They ranged from 58% for 
the Games and Gambling module to 76% for the Experi-
ences of Healthcare module.
Extensive beta testing was conducted by research staff 
at QIMR Berghofer and external consultants to ensure 
that there were no inconsistencies in the questionnaire 
and that the appropriate question skips were in place.
Screenshots of the title page, sections of the question-
naire and the module selection page are shown in online 
supplementary figure 1a- d.
Study measures
As shown in figure 2, a wide range of self- report variables 
of relevance to mental health were collected. For brevity, 
we report only on the primary measures of interest. The 




Participants were asked ‘Have you ever been diagnosed 
with any of the following’ and were presented with a 
list of mental health disorders with ‘Depression’ as the 
first response option. We also evaluated whether partic-
ipants met the 2013 update to the Diagnostic and Statis-
tical Manual of Mental Disorders (DSM-5, American 
Psychiatric Association (2013). Diagnostic and Statistical 
Manual of Mental Disorders (Fifth ed.). Arlington, VA: 
American Psychiatric Publishing. pp 5–25) criteria for 
major depressive disorder using the CIDI. The diagnostic 
questions for depression were focused on the worst period 
of depression that a participant had experienced. Age at 
worst episode as well as the age at which the participant 
had first had a 2- week period of dysphoria or anhedonia 
as well as age at most recent episode were assessed. Partic-
ipants were also asked to report the number of periods of 
at least 2 weeks of dysphoria or anhedonia they had ever 
had.
Antidepressants
To assess whether participants had taken antidepressants 
to treat depression, the question ‘Have you ever taken 
any of the following antidepressants (even if it wasn’t 
for depression or anxiety)?’ was presented with a list of 
the 20 most commonly used antidepressants in Australia 
in addition to their common trade names. If they had 
taken one or more of the 10 most frequently prescribed 
antidepressants in Australia according to PBS records 
(sertraline, escitalopram, venlafaxine, fluoxetine, citalo-
pram, desvenlafaxine, duloxetine, mirtazapine, amitrip-
tyline and paroxetine), they were then asked ‘Why were 
you prescribed (name of antidepressant)’. The focus on 
collecting more detailed information on the 10 most 
common antidepressants was so as to align with the 
recruitment criteria from the PBS.
Benefits and side effects of the 10 most common antidepressants
Perceived effectiveness of each antidepressant medication 
was assessed by asking participants ‘How well does/did 
(name of antidepressant) work for you?’, with response 
options of ‘very well’, ‘moderately well’, ‘not at all well’ 
and ‘don’t know’. Participants were also asked to select 
from a list of all side effects that they experienced from 
taking each antidepressant. The list of side effects was 
generated from the ‘very common’ (frequency ≥10%) 
and ‘common’ (frequency ≥1% and<10%) side effects 
listed in the Consumer Medication Information for each 
antidepressant. A total of 24 side effects were included 
with an ‘other’ option also provided. Participants were 
also asked if they stopped taking any of the antidepres-
sants because of side effects.
Saliva collection and DNA extraction
Several brands of saliva DNA kits were tested for suit-
ability for use, including cost, ease of handling and yield 
and quality of extracted DNA. Among those with the best 
quality reports, the Isohelix GeneFix GFX-02 2 mL saliva 
collector was selected due to it being the most compact, 
reliable, easy to use, lightweight, and therefore the least 
expensive to mail to participants.
After completing the core module of the question-
naire, participants were emailed to confirm their delivery 
address and their readiness to receive a saliva DNA kit. 
On confirmation, they were mailed a spit kit, together 
with a consent form specific to the treatment of genetic 
information to be signed and returned with the tube. We 
found that this confirmation step markedly increased 
compliance. Saliva samples were returned by study partic-
ipants by prepaid post. If the kit was not returned after 2 
months, study personnel followed up by phone or email 
in order to maximise return rates. On return of the kit, 
DNA was extracted from the saliva sample and stored in 
freezers.
Genotyping was conducted using the Illumina Global 
Screening Array V.2.0 (GSA) and is now ready for anal-
ysis. GSA was developed by human genetic disease 
researchers to maximise utility for gene mapping. It 
includes a common variant backbone component that 
maximises information for imputation of common vari-
ants in multiple ethnic populations as well as a suite of 
common and rare variants selected for known or likely 
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Figure 3 Age distribution by sex of participants in AGDS. 
AGDS, Australian Genetics of Depression Study.
association with a range of genetic disorders. Importantly 
for the purposes of this study, it includes several genetic 
variants with known pharmacogenetic associations from 
the Pharmacogenomics Knowledgebase (PharmGKB, 
https://www. pharmgkb. org/).
Participant and patient involvement
Patients were not consulted directly about the design of 
the study but a number of psychiatrists were consulted to 
ensure that the outcome measures reflect the variety of 
patient experiences seen in clinical practice. Two partic-
ipants were featured in the promotional material and 
press conference for the study to encourage others with 
a history of clinical depression to enrol in the study. All 
papers that include data from the cohort will be sent to 
participants via email.
Controls—the Qskin study
The primary aim of the AGDS was to recruit as many indi-
viduals with depression as possible. There was no publicity 
initiated to recruit controls because an appropriate 
control sample is available at QIMR Berghofer from the 
QSkin Sun & Health Study. QSkin was established in 2010 
to investigate risk factors for melanoma and other skin 
cancers in a randomly sampled cohort of individuals aged 
between 40 and 69 years from the state of Queensland.17 
To date, more than 40 000 participants have enrolled in 
QSkin. Recently, a genetics arm of the study was initiated 
following a similar protocol for collection of DNA using 
saliva kits returned by mail. At the time of saliva collec-
tion, participants were asked about their medical history, 
including whether they have ever been diagnosed with or 
treated for depression, bipolar disorder, schizophrenia/
psychosis, anxiety, obsessive compulsive disorder, bulimia, 
anorexia nervosa, autism or attention deficit hyperac-
tivity disorder (ADHD). In addition, women were asked 
if they experienced either antenatal or postnatal depres-
sion. Moreover, participants were consented for access 
to MBS and PBS records which will permit screening for 
use of antidepressants in addition to the disease checklist 
screening items above. QSkin is a separate study to the 
AGDS and hence the QSkin participants did not complete 
the detailed questionnaire used in the AGDS.
More than 18 000 participants have been genotyped 
on the same Single Nucleotide Polymorphism (SNP) 
microarray chip—the Illumina GSA—and the genotype 
data will be merged with the AGDS study prior to genome- 
wide imputation. The QSkin study thus provides a large 
sample of Australian controls selected at random from 
the population and genotyped on the same SNP chip.
results
sample characteristics
As of 3 September 2018, questionnaire responses had 
been received from 20 689 participants, 75% of whom 
were female. The age distribution of participants, by sex, 
is shown for this recruitment wave in figure 3. By the same 
date, saliva samples were returned by 15 807 participants 
(76% of the participant group). The average age of partic-
ipants was 43 years±15 years (range 18–90 years), with the 
demographic characteristics of the cohort, as a function 
of recruitment method, being outlined in table 1.
Findings to date
Mental health history
Among respondents, 98.5% reported having discussed 
mental health problems with a professional and 19 803 
(93.4%) respondents reported having received a diag-
nosis of depression. The next most commonly reported 
diagnoses were anxiety disorder (55.0%), post- traumatic 
stress disorder (14.0%) and social anxiety disorder 
(11.4%). The frequency of all self- reported diagnoses is 
shown in table 2.
Depression diagnosed by CIDI
The DSM-5 outlines the following criteria for a depressive 
episode: dysphoria and/or anhedonia most of the day, 
nearly every day for at least 2 weeks and experiencing at 
least five out of nine symptoms (including dysphoria or 
anhedonia). Consistent with the high rates of self- report 
diagnosis in the sample, 17 698 out of 20 165 individuals 
who completed the depression screening section met 
the criteria for a depressive episode. Additionally, 358 
individuals reported not having had a 2- week period of 
dysphoria or anhedonia; another 1239 reported that their 
symptoms persisted for less than half the day and 161 did 
not endorse at least five of the nine symptoms required.
Mean age at onset was 22. The distribution of age at 
onset by sex is shown in figure 4. Consistent with previous 
studies, the peaks between ages 10–15 and 16–20 high-
light that adolescence is a peak time for developing 
depression. The proportion of men in each category 
increases with increasing age, highlighting that men are 
more at risk to develop depression later in life.
The median number of episodes reported was 6, with 
the most commonly reported number of periods of at 
least 2 weeks with depression being 13+. Only 4% of the 
sample report experiencing only one depressive episode 
(figure 5), indicating that the sample is enriched for 
severe, recurrent depression.
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Table 1 Demographic and study participation characteristics of the study sample
Prescription history 
invitation Public appeal Total in AGDS
QSkin (genotyped 
sample)
Number of participants 2963 17 726 20 689 17 218
Age in years
  Mean (SD) 45.5 (16.3) 42.3 (15.1) 42.8 (15.3) 60.8 (8.9)
  Range 18 – 89 18 – 90 18 – 90 43 – 87
Sex
  Female 2192 (74%) 13 323 (75%) 15 515 (75%) 9469 (55%)
  Male 771 (26%) 4376 (25%) 5147 (25%) 7749 (45%)
  Unspecified 0 (0%) 27 (0.2%) 27 (0.1%) 0 (0%)
Marital status N/A
  Never married 788 (27%) 5604 (32%) 6392 (31%)
  Married/de facto relationship 1678 (57%) 9079 (51%) 10757 (52%)
  Separated/divorced 423 (14%) 2733 (15%) 3156 (15%)
  Widowed 64 (2%) 276 (1.5%) 340 (1.6%)
  Information not provided 10 (0.3%) 34 (0.2%) 44 (0.2%)
Education (completed or partially 
completed)
  Junior high school or less 286 (9%) 842 (5%) 1118 (5.4%) 1003 (6%)
  Senior high school 318 (11%) 1283 (7%) 1601 (7.7%) 5568 (31%)
  Certificate or diploma 819 (28%) 3653 (21%) 4472 (22%) 5001 (28%)
  Degree 772 (26%) 5837 (33%) 6609 (32%) 4960 (28%)*
  Postgraduate 556 (19%) 4448 (25%) 5004 (24%)
  Information not provided 212 (7%) 1663 (9%) 1885 (10%) 1104 (6%)
Provided saliva sample 2217 (75%) 13 339 (76%) 15 616 (76%) 17 218 (100%)
Permitted Medicare and PBS data 
access
2637 (89%) 13 117 (74%) 15 754 (76%) 16 482 (95.7%)
*In the QSkin sample, participants were not asked whether they had a postgraduate degree. Those with postgraduate degrees will be 
included in the degree category.
PBS, Pharmaceutical Benefits Scheme.
The median duration of the worst episode was 12 
weeks. More than 10% of the sample reported that the 
worst episode that they experienced was longer than a 
year in duration (figure 6).
Family history
Out of 19 400 individuals who responded to the ques-
tion about family history, 13 505 (70%) reported that a 
first- degree relative (parent, sibling or child) had been 
diagnosed with a mental health disorder. The most 
commonly reported diagnosis in relatives was depression, 
(with 11 929 individuals), followed by generalised anxiety 
disorder and bipolar disorder (figure 7).
Antidepressant usage
A total of 95% of the sample (n=19 585) reported taking 
an antidepressant. Of those reporting antidepressant use, 
93% (n=18 174) reported taking the antidepressant for 
depression and 51% reported taking for anxiety.
Among those taking antidepressants, the mean number 
of antidepressants taken was 2.75 (SD=2.05, range=1–14). 
Only 33% of the sample had ever taken only one antide-
pressant, with 42% reporting having taken three or more 
different antidepressants (figure 8).
For the 10 most common antidepressants listed, the 
number and percentage of participants with experi-
ences of each medication are shown in table 3. Reported 
effectiveness of the 10 most common antidepressants is 
shown in figure 9. The rates of endorsement of the most 
common side effects across the 10 most common antide-
pressants are shown in table 4. More detailed analyses on 
the therapeutic benefits and side effects of different anti-
depressants will follow in subsequent papers.
dIsCussIon
The AGDS was established to recruit a large sample of 
participants in Australia who have experienced depression 
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Depression 19 603 94.7
Anxiety disorder 11 375 55.0
PTSD 2900 14.0
Social anxiety disorder 2359 11.4
Panic disorder 1960 9.5
Bipolar 1943 9.4
Personality disorder 1200 5.9
Obsessive compulsive disorder 1175 5.8
ADD/ADHD 847 4.1
Substance use disorder 764 3.7
Anorexia Nervosa 731 3.6
Specific phobia 724 3.6
Bulimia nervosa 638 3.1




Hoarding disorder 100 0.5
Tourette's 27 0.1
Participants may report more than one diagnosis.
ADD, attention deficit disorder; ADHD, attention- deficit 
hyperactivity disorder; PTSD, post- traumatic stress disorder.
Figure 4 Age at onset of depression by sex.
Figure 5 Number of reported depressive episodes among 
those meeting the criteria for major depressive disorder by 
sex.
Figure 6 Duration of worst depressive episode by sex. 
AGDS, Australian Genetics of Depression Study.
in order to better understand risk factors for depression, 
treatment response and side effects. Participants provided 
extensive information on their experience with depres-
sion through a web- based questionnaire and the majority 
provided a saliva sample for genotyping. Through two 
modes of recruitment—government medical and phar-
maceutical records and a large media campaign—more 
than 20 000 individuals were recruited to participate 
over a 2- year period. With extensive follow- up through 
email and, at the stage of getting saliva samples returned, 
phone follow- up by experienced interviewers, 76% of 
those enrolled returned a saliva sample.
The media campaign was the more successful of the two 
methods as more than 80% of the sample was recruited in 
this way. Approximately 2.5% of those sent letters by the 
DHS enrolled in the study. There may be several reasons 
for the low rate of participation from this method. First, as 
antidepressants are prescribed for a range of conditions, 
many of those sent letters may not have had depression 
and hence decided not to participate. Second, letters may 
be easily discarded by recipients as unsolicited mail may 
not be well received. Lastly, the media campaign included 
interviews with both study investigators and individuals with 
lived experience of depression who encouraged others to 
participate. As more information can be conveyed about 
the importance of the research through a TV or radio inter-
view, it likely had a bigger impact on potential participants.
While the media campaign was more effective for this 
study, depression is a relatively common disorder and there-
fore amenable to a media campaign that reaches a substan-
tial proportion of the population. For rarer disorders, 
recruitment through the PBS could be an efficient method 
of reaching potential participants, particularly when a drug 
is used to treat only one disorder and so all those prescribed 
with it will have a diagnosis.
The primary focus of the study was to recruit cases 
because of the availability of the QSkin sample for use 
as controls for genetic analyses. QSkin participants have 
already been genotyped on the same SNP chip. However, 
the Qskin participants were not administered the full ques-
tionnaire and a single question about a prior diagnosis of 
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Figure 7 Frequency of reported diagnoses in first- degree 
relatives of participants. ADHD, attention- deficit/hyperactivity 
disorder; GAD, generalised anxiety disorder; PTSD, post- 
traumatic stress disorder.
Figure 8 Distribution of the number of prescribed 
antidepressants taken by participants. AGDS, Australian 
Genetics of Depression Study.



























Never taken antidepressants 976 4.72
Participants may report taking more than one antidepressant.
AGDS, Australian Genetics of Depression Study.
Figure 9 Reported efficacy of the most commonly 
prescribed antidepressants (numbers with each response are 
shown inside the bar).
psychiatric disorders is used to define controls for inclu-
sion. Some participants may have had depression but did 
not receive a diagnosis and will be incorrectly included as 
controls. The Qskin cohort is older than the AGDS cohort 
(mean age 60.8 years vs 42.8 years). This means that most 
participants are past the peak age at onset for depression 
and are unlikely to go on to be diagnosed with depression.
The mean age among those recruited through the media 
was lower than through the PBS and had higher rates of 
university completion. This suggests that the former may 
be closer to a random sample from the population. Like-
wise, there are differences in the education level (78% 
with a post high school qualification compared with 56%) 
between the case sample from AGDS and the controls from 
QSkin. Some of the differences in education level may be 
a cohort effect attributable to the age difference between 
the cohorts, as the proportion of the population with 
tertiary qualifications is increasing over time. According 
to Australian census data, the proportion of the popula-
tion with a post school qualification increased from 46% 
to 56% between 2006 and 2016.18 However, there may be 
a response bias whereby participants with higher levels of 
education are more likely to enrol in a genetic study. Higher 
levels of education have been found to be associated with 
participation in the optional components of volunteer 
studies such as the Avon Longitudinal Study of Parents and 
Children19 20 and UK Biobank.21 22 These differences could 
confound genetic association results and therefore we will 
conduct a number of sensitivity analyses such as comparing 
only cases and controls with matched education levels to 
investigate the influence of education differences on the 
analyses. Likewise, we will compare differences between 
those who returned a spit kit and those who did not return 
a kit to assess whether there is response bias that needs to 
be addressed.
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Table 4 Proportion of all individuals who have taken one of 
the top 10 most commonly prescribed antidepressants that 



























Volunteer participation could also cause bias towards 
recruiting participants with less severe forms of depres-
sion. We will endeavour to investigate this response bias 
by comparing results from our analyses with those from 
smaller datasets recruited in clinical settings and to other 
datasets with a broad spectrum of severity of depression. 
It has been shown that those with more severe depression 
have higher mean polygenic risk scores for depression than 
those with less severe depression. By comparing the distri-
bution of polygenic risk scores to other samples, we can 
assess the effect of response bias on the severity of depres-
sion in AGDS. Our initial analyses suggest that many of 
the participants have had severe depression as they report 
large numbers of episodes and nearly 50% report having 
had symptoms in the past 4 weeks. Likewise, the reported 
rates of response to the first prescribed antidepressant 
are nearly identical to those from the STAR*D clinical 
trial (33%).23Based on the self- report data on number of 
episodes and other measures of severity, the AGDS sample 
has high rates of severe depression.
Our results highlight the high rate of comorbidities with 
depressive disorders in real- world settings.24 Understanding 
the pattern of comorbidities and how it relates to response 
to treatment, emergence of side effects (eg, greater anxiety 
or agitation in those with comorbid anxiety disorders), and 
underlying genetic variations are aspects of the disorder 
that this scale of study can address. Specifically it will be 
of interest to test if there are different genetic or environ-
mental risk factors to onset, course of illness, response to 
pharmacological treatment or emergence of specific side 
effects for those with depression and comorbid anxiety 
compared with depression without anxiety. In addition, 
we will test specific proposed subtypes of depression (eg, 
perinatal depression, atypical depression, chronic depres-
sion, early- onset vs late- onset depression or depression 
with hypomanic or brief manic features) that may show 
evidence of distinct genetic risk factors for onset or treat-
ment response.
Participants reported high rates of mental disorders in 
their first- degree relatives, highlighting the well- established 
genetic component of and the covariance between psychi-
atric disorders.25 High rates of familial disorders may reflect 
that participants were more likely to participate in a genetic 
study if they have a family history or that participants shared 
details of the study with family members. Familial relation-
ships within the participants will be controlled for in future 
genetic analyses.
Nearly half of participants reported taking three or more 
antidepressants to treat depression and thus having consid-
erable time to improvement in symptoms. Moreover, side 
effects are common and in many cases cause individuals to 
stop taking a drug. These results confirm the urgent need 
to identify risk factors for non- response to certain drugs and 
to reduce side effects. Not only will such advances improve 
the lives of patients but they will also assist to reduce costs 
attributable to delays in achieving illness remission. When 
PBS records become available, we will be able to investi-
gate the concordance with self- report information on drug 
response over the past 4.5 years. In collecting a wide range 
of environmental, social and genetic data, AGDS will make 
a significant contribution to our understanding of vari-
ability in response and side effects.
CollAborAtIon
We have established a cohort with rich information on 
history of mental illness and use of antidepressant medica-
tion use. A primary motivation for establishing this cohort 
was to contribute to global efforts to identify genetic risk 
factors for depression and treatment response through 
the PGC. Summary genetic association statistics for this 
cohort will be available through the PGC. We encourage 
collaborations with researchers from other studies to inves-
tigate the aetiology of complex traits ascertained in AGDS 
to maximise sample sizes for analysis. The full question-
naire is available in the online supplementary material. 
Researchers are encouraged to contact Nick Martin ( nick. 
martin@ qimrberghofer. edu. au) to discuss collaboration. 
All proposals will be reviewed by the principal investigators 
of the AGDS.
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